Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, with the JDRF tweeting about our diabetes treatment, we are getting more exposure with big pharma. We have a real good chance to cure diabetes. I think they should be looking to collaborate with us...
.@PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program https://t.co/Je63Gjbp8W via @CNNMoney #T1D
— Breakthrough T1D (@BreakthroughT1D) December 29, 2015
Absolutely and I really like what KW said in the PR yesterday.
"Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”
:)
Ken Waggoner has done and continues to do great things for this company. And I continue to support his and all of the doctors' efforts to get this technology to patients. I don't think there is a "we" chance here.
Quote, "We need to stand up and expose people like that."
I am a believer in this technology. I am keeping my thoughts focused on our success... Thanks
Cheap shots happen often and like I have said before, "Stand for something, or fall for anything."
$PMCB STRONG!
Good morning and Happy New Year to all... Looking forward to what the new year will bring for PMCB...
Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
SOURCE Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, N.Y., Dec. 30, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.
John S. Kovach M.D., founder and president of Lixte, said "LB-100 is a novel small molecule that in preclinical studies has activity against a number of different cancer types alone and, most prominently, in combination with cytotoxic drugs, including some known to be active against hepatocellular carcinoma. We welcome an opportunity to work with an outstanding group of investigators in Taiwan to assess the value of LB-100 against this all-too-common and devastating cancer."
HCC is the fifth most common cancer and third most common cause of cancer deaths worldwide, with the majority of those deaths in Asia. The World Cancer Research Fund International reported that 782,000 new cases were diagnosed in 2012 worldwide. There are approximately 35,000 new cases and 24,000 deaths from HCC annually in the US according to the National Cancer Institute.
Taipei Medical University has nine colleges, thirteen undergraduate schools, fifteen graduate institutes, as well as three affiliated hospitals with approximately three thousand beds. TMU is one of the largest health care systems in Taipei, providing teaching, research and clinical services. In 2012 they established the Taipei Cancer Center, the first world-class cancer center in Taiwan, combining cancer research, training and clinical treatment, dedicated to providing the full spectrum of services for adult and pediatric oncology.
http://www.newson6.com/story/30852953/lixte-biotechnology-holdings-inc-announces-exclusive-licensing-of-their-lead-anti-cancer-compound-lb-100-for-potential-treatment-of-hepatocellular
That is awesome to see the JDRF tweeting about our diabetes treatment and the great video that explains our diabetes program. This is pretty significant. Thanks for the post
Didn't know that. Thanks...
Merry Christmas...
Congratulations! Great news for all believers. :)
I use to always wonder why so many would even bother watching a pig, but now I truly understand.
When a R&D biotech has no revenue, dilution for trials and research as well as delays (due to the "nature" of the business), it is such an easy target. And the lower the buy-in price the higher the profits some can make on small successes shared in a PR, only to purchase more on the downside and sell on the small upside again.
It is a pattern easily tracked.
I just hope all those who believe in this technology keep this truth in mind and stay the course.
"Stand for something or fall for anything."
http://otcshortreport.com/index.php?index=Pmcb&action=view#.Vm-oRK876rU
Great post, Rudy...
Typical R&D biotech.
We should be hearing soon about the visit to the Thailand facility which will give us some indication on our progress toward cGMP.
It's not easy, I know, to watch the pps drop but if you believe in the technology, you must know there is the potential for a huge upside here. I do believe in this technology so even though it is difficult to wait, I will do it because I personally want to be a part of this journey.
I concur Jimmy Joe. Warren Buffet's quote about trying to make a baby in one month especially applies to the bio sector and people do take advantage of that fact.
Holding for the long-term here...
Sorry but it is pretty evident who is talking and what he is saying. It is even more important to take note of actions. Since the release of this video, TD2 has decided to join PMCB in it's phase 2b trial in addition to pursuing Phase 1 for malignant ascites.
Actions do speak louder than words. He was interested and he still is interested.
Anyone can hear this same information from the CEO of TD2, Stephen Gately, "if" they are willing to hear it...
Circa 17:00 minutes in the corporal video...
http://www.pharmacytebiotech.com/media/
Yes, I do think their technology has a chance to be a big hitter. So do a lot of world renowned doctors.
Dr Von Hoff saw previous data from Austrianova trials and contacted our CEO wanting to do some preclinicals with Cell in a Box. His team at TD2 did preclinicals for malignant ascites. Now they are joining us in our 2b pancreatic cancer trials and starting clinical trials for malignant ascites.
Diabetes also looks to be a winner in that there will be no need for insulin shots for type 1 diabetes using our treatment. We are currently in preclinicals for diabetes.
GLTU
The previous study with Dr Lohr mentioned in today's PR is the one that showed complete tumor remission. Very excited to be following this same model. Great news today...
http://finance.yahoo.com/news/pharmacyte-biotechs-cancer-treatment-shows-133000454.html
Malignant ascites for all abdominal cancers. Very good news here. We will have several significant trials going on about the same time. Very excited for Cell in a Box to start treating patients...
Canadian Trader has a real nice sticky that I have been looking over. Things are looking pretty good here... GLTU...
Hey, LoveAndLight. Thanks so much for your contact. I will do some updated DD on RGBP. Don't have PM. :). Nice close today...
Also well said... :)
Great post. Thanks...
Hear! Hear! I am in for the long-term. I guess you can make money on a 2 cent spread but knowing what I know, having done DD on PMCB, I prefer to hold for the bigger pay out.
If you have ever read any of his articles you will see that he provides a lot of good information to stockholders in an effort to help them understand the science. I would surmise he was there to learn so he could do what he does best, and share the diabetes story.
PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study
NEW YORK, NY — PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.
It was a study that used a colon cancer model to treat malignant ascites, a fluid that is common with abdominal cancers like pancreatic, colon, ovarian and liver cancer that accumulates in the abdominal cavity and causes painful swelling of the stomach. In PharmaCyte Biotech’s corporate video (www.PharmaCyte.com/media), renowned gastroenterologist and oncologist, Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, says that he and a team of doctors and researchers found that they “could virtually cure malignant ascites” in this study.
Readers can find the published preclinical study in Cancer Gene Therapy here: http://www.nature.com/cgt/journal/v13/n1/full/7700849a.html
The preclinical study, commissioned by Bavarian Nordic, used “targeted chemotherapy” to treat malignant ascites just as PharmaCyte biotech does. In the study, words like “complete tumor remission” and “cure” were used to describe the results, so why didn’t Bavarian Nordic continue on with its work?
Well, at the time of the study, Bavarian Nordic, the forerunner to Austrianova, had three in-house technologies: (i) the encapsulation technology; (ii) a retroviral vector technology; and (iii) a poxvirus based delivery platform. As a result of the attacks of 9/11 in the United States, Bavarian Nordic decided to focus strategically on the development of a smallpox vaccine based on its poxvirus platform and chose to divest the other two technologies, which eventually were moved into Austrianova.
Austrianova GmbH, based in Europe then, was focused on one big indication – namely pancreatic cancer. Executives at Austrianova made the decision then to go straight into a pivotal Phase 3 clinical trial in pancreatic cancer, which would have cost the biotech about $40 million. Austrianova was also working on setting up the GMP manufacturing facility in Frankfurt, Germany, and the firm was working on a veterinary clinical trial in mammary cancer.
Prof. Dr. Walter Gunzburg, the Chairman and Chief Technical Officer at Austrianova, said that the company didn’t have the manpower or the resources to work on malignant ascites in addition to all of its other planned activities. “Despite the exciting results in ascites published by Dr. Matthias Löhr, the financial resources available to the company (Austrianova GmbH) in Europe at that time didn’t allow us to pursue this indication. We are very glad that PharmaCyte Biotech has now taken up the baton and is again exploring the use of the Cell-in-a-Box® technology to develop a clinical treatment for malignant ascites.”
If this study sounds familiar, it’s because PharmaCyte is currently in preclinical studies with Translational Drug Development (TD2) in Scottsdale, Arizona, to study how effective its treatment can be on the accumulation of malignant ascites. Dr. Löhr, who is now the Chairman of PharmaCyte Biotech’s Scientific Advisory Board, has been involved with the TD2 study from day one.
In the TD2 study, the company is using an ovarian cancer model and working to develop the parameters needed to enter into clinical trials. Based on comments in press releases from PharmaCyte’s CEO, Kenneth L. Waggoner, the company’s treatment appears promising, and plans are being made to enter the clinic to tackle the challenges that malignant ascites presents to patients who have abdominal tumors.
While the studies performed by Dr. Löhr and his team using the colon cancer model were more than 10 years ago, it is quite stunning to hear that they were not only able to “virtually cure malignant ascites” but they also saw “complete tumor remission in all animals” treated with Cell-in-a-Box® (known as Capcell then) and low doses of ifosfamide on days 2-6.
It’s stunning because more than 10 years ago Cell-in-Box® wasn’t nearly as developed as it is today. The technology is much improved in 2015 with capsules that are completely full with active live cells. So, with a more “potent” Cell in a Box® today, patients suffering from malignant ascites from one of the abdominal tumors that causes the accumulation of this fluid, must be elated to see PharmaCyte Biotech reviving the studies to treat this condition where there is currently no treatment available other than the painful and expensive periodic removal of the fluid in a hospital setting.
http://www.stockmarketmediagroup.com/pharmacyte-biotechs-cancer-treatment-shows-complete-tumor-remission-in-published-preclinical-study/
I think it is noteworthy that Dr Von Hoff contacted Ken Waggoner wanting to work with Cell in a Box after "seeing the data", which had to be 10 year old data... and yet he was still interested.
Then, we have the pre-clinical studies with reportedly good results from the CEO.
Then, not only do we continue to plan for P1 malignant ascites trials with TD2, but now they are also joining us in our P2B trials for pancreatic cancer. PMCB will now be working in tandem with the gold standard (CELG). Also, we will able to reach many more patients as a result of these enhancements reducing the time needed to complete trials.
Now I have always learned that 1 + 1 = 2. Negative preclinical studies would certainly not be a + nor lead to human trials. I would surmise that the additional support from TD2, who conducted the preclinicals, supports KWs claim that the results were very good.
Corporate video circa 17:00. http://www.pharmacytebiotech.com/media/
I am thinking the same thing bull...
Naysaying does not alter the truth nor does it divert the company from its laser focus. Some like to take advantage of lag times and create concern. All the while our team is working tirelessly to accomplish every milestone needed to get Cell in a Box to patient treatment.
"Patients and patience will be rewarded."
Hey bill, good to see you. Yep, very good news yesterday....
JDT, I don't think it was them. They are pretty good about keeping us informed. I think they would have told us beforehand if the application included ascites. Although, I am all for surprises. :)
I like it! :)
If you look at the history of Anovasia you will see they have been around since at least 2012. We did not even come in the picture until 2013 when we got exclusive rights to cancer for use with CiaB. Additionally, their business model is completely different. They are focused on Molecular Painting...
http://anovasia.com/timeline/4565236343
Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity
EAST SETAUKET, N.Y., Nov. 6, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that in an ongoing Phase I trial its lead anti-cancer compound, LB-100, was associated with stabilization of a variety of advanced cancers that had been progressing despite extensive prior treatment. The results were presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, on November 6. The authors were Vincent Chung, City of Hope, Duarte, CA; Donald Richards, Texas Oncology, Tyler, TX; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; John S. Kovach, Lixte Biotechnology Holdings, Inc., East Setauket, NY; Aaron Scott Mansfield, Mayo Clinic, Rochester, MN.
A total of 21 patients received LB-100 for 3-consecutive days in 3-week cycles. Nine of these patients had stabilization of their disease without significant toxicity. One patient with pancreatic cancer received 14 cycles of LB-100 (42 weeks); one with thymoma, 9 cycles; one with testicular and one with carcinoid of the lung, 5 cycles; two with ovarian, 3 and 6 cycles; and one with NSCLC and one with duodenal cancer, 3 cycles. The average number of cycles received at the last four evaluable dose levels of LB-100 was 4.8 (14.4 weeks). In a study by Mansfield et al (2015 JCO 33[15] suppl:2567), the average number of cycles of a new drug in 51 NCI-sponsored Phase 1 trials conducted from 1994-2014 involving 1841 patients was 2.0 (6-8 weeks).
John S. Kovach M.D., founder and president of Lixte, said "Lixte interprets the results as showing that LB-100 has single agent activity in suppressing the growth of several types of cancer. What is highly encouraging is that stabilization of disease occurred in the absence of dose-limiting toxicity. In fact, most patients tolerated repeated doses without any ill-effects. As pre-clinical studies have shown that LB-100 potentiates the effectiveness of cytotoxic agents, we believe that LB-100 alone and in combination with standard anti-cancer drugs and/or radiation may offer new therapeutic options for a spectrum of neoplastic diseases."
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the Company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is in a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCT01837667).
Forward-Looking Statements
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.
Additional information on the Company is available at www.lixte.com.
Corporate Contact:
Eric J. Forman, Esq.
646-894-3135
eforman@lixte.com
SOURCE Lixte Biotechnology Holdings
Fugazi's are every where, bio. :)
Fugazi defined...
1. Artificial, fake. Something that has no substance.
http://www.urbandictionary.com/define.php?term=fugazi&defid=1373631
Great DD Rudy...
Fisher actually owns over 344k as of last quarter...
http://finance.yahoo.com/q/mh?s=PMCB+Major+Holders
I am showing Fisher went from 11k to over 344k this last quarter... Good luck on your purchase and welcome...
http://finance.yahoo.com/q/mh?s=PMCB+Major+Holders
Mirna Therapeutics Announces Presentation of Interim Data from Ongoing Phase I Clinical Trial of MRX34, First-in-Class microR...
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the presentation of interim results from its ongoing Phase 1 clinical trial of MRX34, the Company’s lead therapeutic product candidate.1 The poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, reported interim Phase 1 clinical results for MRX34 from 75 patients with advanced solid tumors. MRX34 is a double-stranded “mimic” of the naturally occurring tumor suppressor microRNA (miRNA) miR-34, encapsulated in the SMARTICLES® liposomal delivery formulation.
Interim safety, efficacy and biomarker data from the multicenter, open-label Phase 1 clinical trial in solid tumor patients show that MRX34 has a safety profile manageable with standard interventions or tests used by oncologists, and demonstrate the therapeutic potential of miR-34 replacement therapy. Additionally, dose-dependent effects on miR-34 target genes in patients’ white blood cells have been observed. As of August 13, 2015, two patients with advanced, metastatic Stage IV cancer have achieved clinical responses after treatment with MRX34: one patient with primary liver cancer (hepatocellular carcinoma, HCC) metastatic to the lung, and one patient with acral melanoma, metastatic to lymph nodes, showed more than 30 percent tumor shrinkage (confirmed partial responses).
The findings were presented on Sunday, November 8, in a poster presentation entitled “Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors” by primary author Muhammad Shaalan Beg, M.D., Assistant Professor, Internal Medicine, University of Texas Southwestern Medical Center.
“These results further confirm our excitement about the MRX34 program, demonstrating early, promising therapeutic potential of microRNA replacement therapy in patients with advanced Stage IV cancer,” commented Paul Lammers, M.D., President and Chief Executive Officer of Mirna. “We look forward to the expansion phase of this trial in which we expect to enroll more patients with these as well as other cancer types.”
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the presentation of interim results from its ongoing Phase 1 clinical trial of MRX34, the Company’s lead therapeutic product candidate.1 The poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, reported interim Phase 1 clinical results for MRX34 from 75 patients with advanced solid tumors. MRX34 is a double-stranded “mimic” of the naturally occurring tumor suppressor microRNA (miRNA) miR-34, encapsulated in the SMARTICLES® liposomal delivery formulation.
Interim safety, efficacy and biomarker data from the multicenter, open-label Phase 1 clinical trial in solid tumor patients show that MRX34 has a safety profile manageable with standard interventions or tests used by oncologists, and demonstrate the therapeutic potential of miR-34 replacement therapy. Additionally, dose-dependent effects on miR-34 target genes in patients’ white blood cells have been observed. As of August 13, 2015, two patients with advanced, metastatic Stage IV cancer have achieved clinical responses after treatment with MRX34: one patient with primary liver cancer (hepatocellular carcinoma, HCC) metastatic to the lung, and one patient with acral melanoma, metastatic to lymph nodes, showed more than 30 percent tumor shrinkage (confirmed partial responses).
The findings were presented on Sunday, November 8, in a poster presentation entitled “Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors” by primary author Muhammad Shaalan Beg, M.D., Assistant Professor, Internal Medicine, University of Texas Southwestern Medical Center.
“These results further confirm our excitement about the MRX34 program, demonstrating early, promising therapeutic potential of microRNA replacement therapy in patients with advanced Stage IV cancer,” commented Paul Lammers, M.D., President and Chief Executive Officer of Mirna. “We look forward to the expansion phase of this trial in which we expect to enroll more patients with these as well as other cancer types.”